Xeris Biopharma Holdings Inc. Common Stock (XERS)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Xeris as a commercial-stage specialty drugmaker, not a speculative story. It sells Gvoke, Keveyis, and Recorlev for endocrine and neurological conditions. Revenue is growing: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $92.1M, up from $71.5M in fiscal Q2 2025, the quarter ended 2025-06-30. FY2025 revenue was $291.8M versus $203.1M in FY2024 and $163.9M in FY2023. FairStock labels it TURNAROUND because it returned to profit after a loss within the last three years: FY2025 net income was $554,000 after FY2024's $54.8M loss and FY2023's $62.3M loss. But the latest filed quarter shows a $31.1M net loss and diluted EPS of -$0.18, so the turnaround is not smooth. The balance sheet looks manageable on D/E of 19.87, and trailing free cash flow is $55.7M, a 3.0% FCF yield. Still, at the 2026-10-13 close of $10.20 and $1.9B market cap, FairStock's metrics look demanding: P/E -102, P/B 106.1, EV/EBITDA 84.85, ROCE 6.13%, Piotroski 3/9, Altman Z 0.78. There is no dividend. The moat is not obvious; a small portfolio of specialty products faces competition and reimbursement pressure. Growth is real, but the company has not yet proven durable profitability. I would want consistent positive net income and cash generation before calling the price bargain. For now, it is a show-me story: sales progress versus renewed losses.

In plain English: Xeris Biopharma sells medicines for hormone and nerve-related diseases. Sales are rising, and the company has been near break-even, but its latest reported quarter showed a large loss, so profits are uneven. Based on current profits and asset value, the stock price looks expensive rather than cheap, even though the business does generate some cash.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer